170 related articles for article (PubMed ID: 37256771)
1. A MOF-Based Potent Ferroptosis Inducer for Enhanced Radiotherapy of Triple Negative Breast Cancer.
Zeng L; Ding S; Cao Y; Li C; Zhao B; Ma Z; Zhou J; Hu Y; Zhang X; Yang Y; Duan G; Bian XW; Tian G
ACS Nano; 2023 Jul; 17(14):13195-13210. PubMed ID: 37256771
[TBL] [Abstract][Full Text] [Related]
2. Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination.
Rao Z; Xia Y; Jia Q; Zhu Y; Wang L; Liu G; Liu X; Yang P; Ning P; Zhang R; Zhang X; Qiao C; Wang Z
J Nanobiotechnology; 2023 Aug; 21(1):265. PubMed ID: 37563614
[TBL] [Abstract][Full Text] [Related]
3. Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy.
Li K; Lin C; Li M; Xu K; He Y; Mao Y; Lu L; Geng W; Li X; Luo Z; Cai K
ACS Nano; 2022 Feb; 16(2):2381-2398. PubMed ID: 35041395
[TBL] [Abstract][Full Text] [Related]
4. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer.
Zhou TJ; Zhang MM; Liu DM; Huang LL; Yu HQ; Wang Y; Xing L; Jiang HL
Biomaterials; 2024 Mar; 305():122447. PubMed ID: 38154441
[TBL] [Abstract][Full Text] [Related]
5. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
6. A Mitochondria-Targeted Ferroptosis Inducer Activated by Glutathione-Responsive Imaging and Depletion for Triple Negative Breast Cancer Theranostics.
Gan H; Huang X; Luo X; Li J; Mo B; Cheng L; Shu Q; Du Z; Tang H; Sun W; Wang L; Luo S; Yu S
Adv Healthc Mater; 2023 Sep; 12(22):e2300220. PubMed ID: 37204240
[TBL] [Abstract][Full Text] [Related]
7. An all-in-one biomimetic iron-small interfering RNA nanoplatform induces ferroptosis for cancer therapy.
Huang S; Le H; Hong G; Chen G; Zhang F; Lu L; Zhang X; Qiu Y; Wang Z; Zhang Q; Ouyang G; Shen J
Acta Biomater; 2022 Aug; 148():244-257. PubMed ID: 35709941
[TBL] [Abstract][Full Text] [Related]
8. A Multifunctional Liposome for Synergistic Chemotherapy with Ferroptosis Activation of Triple-Negative Breast Cancer.
Chai J; Hu J; Wang T; Bao X; Luan J; Wang Y
Mol Pharm; 2024 Feb; 21(2):781-790. PubMed ID: 38153044
[TBL] [Abstract][Full Text] [Related]
9. Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis via Triggered GPX4 Inhibition and Concurrent In Situ Bleomycin Toxification.
Zhou L; Chen J; Li R; Wei L; Xiong H; Wang C; Chai K; Chen M; Zhu Z; Yao T; Lin Y; Dong C; Shi S
Small; 2021 Nov; 17(47):e2103919. PubMed ID: 34623753
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional Sr/Se co-doped ZIF-8 nanozyme for chemo/chemodynamic synergistic tumor therapy
Wu A; Han M; Ni Z; Li H; Chen Y; Yang Z; Feng Y; He Z; Zhen H; Wang X
Theranostics; 2024; 14(5):1939-1955. PubMed ID: 38505601
[No Abstract] [Full Text] [Related]
11. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy.
Chen Y; Yao Z; Liu P; Hu Q; Huang Y; Ping L; Zhang F; Tang H; Wan T; Ping Y; Li B
Acta Biomater; 2023 Mar; 159():275-288. PubMed ID: 36709836
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitor-enhanced nanocatalytic ferroptosis induction for stimuli-responsive dual-modal molecular imaging guided cancer radiosensitization.
Zheng S; Hu H; Hou M; Zhu K; Wu Z; Qi L; Xia H; Liu G; Ren Y; Xu Y; Yan C; Zhao B
Acta Biomater; 2023 May; 162():72-84. PubMed ID: 36931419
[TBL] [Abstract][Full Text] [Related]
13. Hypertoxic self-assembled peptide with dual functions of glutathione depletion and biosynthesis inhibition for selective tumor ferroptosis and pyroptosis.
Gao Y; Li Y; Cao H; Jia H; Wang D; Ren C; Wang Z; Yang C; Liu J
J Nanobiotechnology; 2022 Aug; 20(1):390. PubMed ID: 36045424
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer.
Chen T; Leng J; Tan J; Zhao Y; Xie S; Zhao S; Yan X; Zhu L; Luo J; Kong L; Yin Y
J Med Chem; 2023 Jul; 66(14):10036-10059. PubMed ID: 37452764
[TBL] [Abstract][Full Text] [Related]
15. Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors.
Xu Q; Zhan G; Zhang Z; Yong T; Yang X; Gan L
Theranostics; 2021; 11(4):1937-1952. PubMed ID: 33408790
[TBL] [Abstract][Full Text] [Related]
16. Au-Fe
Wei R; Fu G; Li Z; Liu Y; Qi L; Liu K; Zhao Z; Xue M
J Colloid Interface Sci; 2024 Jun; 663():644-655. PubMed ID: 38430834
[TBL] [Abstract][Full Text] [Related]
17. Iron ion and sulfasalazine-loaded polydopamine nanoparticles for Fenton reaction and glutathione peroxidase 4 inactivation for enhanced cancer ferrotherapy.
Zhu X; Chen Q; Xie L; Chen W; Jiang Y; Song E; Song Y
Acta Biomater; 2022 Jun; 145():210-221. PubMed ID: 35470077
[TBL] [Abstract][Full Text] [Related]
18. Anomanolide C suppresses tumor progression and metastasis by ubiquitinating GPX4-driven autophagy-dependent ferroptosis in triple negative breast cancer.
Chen YM; Xu W; Liu Y; Zhang JH; Yang YY; Wang ZW; Sun DJ; Li H; Liu B; Chen LX
Int J Biol Sci; 2023; 19(8):2531-2550. PubMed ID: 37215985
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F; Xiao Y; Ding JH; Jin X; Ma D; Li DQ; Shi JX; Huang W; Wang YP; Jiang YZ; Shao ZM
Cell Metab; 2023 Jan; 35(1):84-100.e8. PubMed ID: 36257316
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable zwitterionic polymer-cloaked defective metal-organic frameworks for ferroptosis-inducing cancer therapy.
Zhang M; Yao X; Xu J; Song J; Mai S; Zhu W; Zhang Y; Zhu L; Yang W
Int J Pharm; 2024 Apr; 655():124032. PubMed ID: 38521374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
